U.S. Agency for International Development (USAID), Kampala, Uganda.
GHTASC, Credence Management Solutions LLC, supporting the United States Agency for International Development (USAID), Office of HIV/AIDS, Washington, DC, United States.
J Int AIDS Soc. 2023 Jul;26 Suppl 1(Suppl 1):e26122. doi: 10.1002/jia2.26122.
The Uganda Ministry of Health recommends facility- and community-based differentiated antiretroviral therapy (DART) models to support person-centred care for eligible clients receiving antiretroviral therapy (ART). Healthcare workers assess client eligibility for one of six DART models upon initial enrolment; however, client circumstances evolve, and their preferences are not routinely adjusted. We developed a tool to understand the proportion of clients accessing preferred DART models and compared the outcomes of clients accessing preferred DART models to the outcomes of clients not receiving preferred DART models.
We conducted a cross-sectional study. A sample of 6376 clients was selected from 113 referrals, general hospitals and health centres purposely selected from 74 districts. Clients receiving ART accessing care from the sampled sites were eligible for inclusion. Healthcare workers interviewed clients (caretakers of clients under 18), over a 2-week period between January and February 2022 using a client preference tool to elicit whether clients were receiving DART services through their preferred model. Treatment outcomes of viral load test, viral load suppression and missed appointment date were extracted from clients' medical files before or immediately after the interview and de-identified. The descriptive analysis determined the interaction between client preferences and predefined treatment outcomes by comparing outcomes of clients whose care aligned with their preferences to outcomes of clients whose care misaligned with their preferences.
Of 25% (1573/6376) of clients not accessing their preferred DART model, 56% were on facility-based individual management and 35% preferred fast-track drug refills model. Viral load coverage was 87% for clients accessing preferred DART models compared to 68% among clients not accessing their preferred model. Viral load suppression was higher among clients who accessed the preferred DART model (85%) compared to (68%) clients who did not access their preferred DART model. Missed appointments were lower at 29% for clients who accessed preferred DART models compared to 40% among clients not enrolled in the DART model of their choice.
Clients who accessed their preferred DART model have better clinical outcomes. Preferences should be integrated throughout health systems, improvement interventions, policies and research efforts to ensure client-centred care and client autonomy.
乌干达卫生部建议采用基于机构和社区的差异化抗逆转录病毒治疗(DART)模式,为符合条件的接受抗逆转录病毒治疗(ART)的患者提供以患者为中心的护理。医护人员在初次登记时评估患者是否符合六种 DART 模式中的一种;然而,患者的情况会发生变化,他们的偏好通常不会得到调整。我们开发了一种工具来了解患者接受偏好 DART 模式的比例,并将接受偏好 DART 模式的患者的治疗结果与未接受偏好 DART 模式的患者的治疗结果进行比较。
我们进行了一项横断面研究。从 74 个地区的 113 个转诊机构、综合医院和卫生中心有目的地选择了 6376 名接受 ART 治疗的患者样本。接受采样点提供的护理的接受 ART 治疗的患者符合纳入条件。医护人员在 2022 年 1 月至 2 月期间使用患者偏好工具对患者(18 岁以下患者的看护者)进行了为期两周的访谈,以了解患者是否通过其首选模式接受 DART 服务。在访谈之前或之后立即从患者的医疗档案中提取病毒载量检测、病毒载量抑制和错过预约日期的治疗结果,并进行去识别处理。通过比较与偏好相符的患者的治疗结果和与偏好不符的患者的治疗结果,描述性分析确定了患者偏好与预定义治疗结果之间的相互作用。
在未接受其首选 DART 模式的患者中(25%,1573/6376),56%接受基于机构的个体管理,35%偏好快速药物续药模式。接受首选 DART 模式的患者的病毒载量覆盖率为 87%,而未接受首选模型的患者为 68%。接受首选 DART 模型的患者的病毒载量抑制率较高(85%),而未接受首选 DART 模型的患者为 68%。接受首选 DART 模型的患者的预约失约率较低,为 29%,而未参加首选 DART 模型的患者为 40%。
接受首选 DART 模式的患者的临床结果更好。偏好应纳入整个卫生系统、改善干预措施、政策和研究工作中,以确保以患者为中心的护理和患者自主权。